Astrana Health Tells SEC Hack Exposed Sensitive Data

Astrana Health notified the SEC of a data breach caused by a social engineering attack, potentially exposing patient, provider, and corporate data. The company is investigating and has taken remedial actions. Astrana, with 2025 revenue of $3.2B, stated the incident is material but does not expect it to affect its financial condition or operations. The company has cyber insurance but cannot guarantee it will cover all losses.

Original reporting
Published Sep 28, 2026, 11:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 29, 2026, 12:23 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefRegulation
Primary signal
MARKET
Neutral
AI market analysis
Mentioned
$ASTH
Relevance
6/10
AlphAI data visualization · based on govinfosecurity.com
Decision brief

The 30-second read

Low
01

Why it matters

The filing is the first public disclosure of the incident, making it a primary source of new information for investors.

02

Market read

First‑report of a material cyber breach at a mid‑cap healthcare services firm; may affect stock perception and sector risk assessment.

03

What to watch

Potential regulatory fines and reputational damage could affect partner contracts.

Relevance 6/10Novelty 7/10Timing: today

Background

Astrana Health disclosed a material cyber‑security breach to the SEC, describing the attack, data types potentially exposed, and remediation steps.

Market effects

Highlights cybersecurity risk for healthcare services firms.

May raise scrutiny of US healthcare providers with similar data practices.

Adds to broader concerns about social‑engineering attacks on listed companies.

Counterpoint

The breach may be over‑stated; insurance coverage could limit financial fallout.

Key entities

  • Astrana Health

    California‑based managed services organization in the healthcare sector.

Related articles

$ASTHMed

Why Astrana Health (ASTH) Shares Are Trading Lower Today

Astrana Health (ASTH) shares fell 5.5% after disclosing a cybersecurity incident and data breach at its subsidiary, adding to existing pressures from a securities-law investigation and Medicare regulatory concerns. The stock is volatile, down 33.3% from its 52-week high, and up 31.7% year-to-date. Investors are assessing the long-term impact of potential Medicare Advantage reforms on the company's margins.

$ASTHMed

Astrana is latest U.S. healthcare company to face acyberattack

Astrana Health ASTH fell 7% premarket after reporting a 'material' cybersecurity incident at its subsidiary, Astrana Health Management. The breach involved unauthorized access to private/confidential data via social engineering. The company is investigating and stated the incident won't materially impact its financials, as of Sept. 22.

$ASTHMed

Astrana Health, Clover Health, Alignment Healthcare, and Novavax Stocks Trade Down, What You Need To Know

Several healthcare stocks fell after bipartisan lawmakers introduced the Protecting Approved Care Act, which aims to reform Medicare Advantage plans. The bill could increase medical loss ratios and administrative burdens for insurers. Astrana Health (ASTH) fell 2.7%, Clover Health (CLOV) 4.8%, Alignment Healthcare (ALHC) 12.6%, and Novavax (NVAX) 3.6%.

$ASTHMedAI 8/10

Astrana Health (ASTH) Q2 2026 Earnings Call Transcript

Astrana Health (ASTH) reported Q2 2026 revenue of $972.5M, up 49% YoY, and adjusted EBITDA of $68.9M, up 43%. Adjusted EPS was $0.80. Six-month free cash flow was $92.9M. The company reaffirmed full-year revenue guidance of $3.8B to $4.1B and raised adjusted EBITDA guidance to $255M to $280M. Net leverage was 2.26.

$ASTHMedAI 8/10

Astrana Health Inc (ASTH) (Q2 2026) Earnings Call Highlights: Record EPS and Raised

Astrana Health Inc (ASTH) reported Q2 2026 results with record EPS and raised guidance, according to management on its earnings call. The company cited a one-time $15 million Q2 revenue reduction tied to CMS adjustments for ACO REACH 2025 billing, with immaterial net EBITDA impact. It also discussed Medicaid membership attrition, commercial cost trends, and wide Q4 2026 EBITDA guidance of $47-$67 million.